Bryn Mawr Capital Management LLC Invests $231,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Bryn Mawr Capital Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,850 shares of the biopharmaceutical company’s stock, valued at approximately $231,000.

Several other institutional investors and hedge funds have also made changes to their positions in GILD. Nilsine Partners LLC lifted its holdings in Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after acquiring an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. lifted its holdings in Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after acquiring an additional 128 shares during the last quarter. Financial Counselors Inc. lifted its holdings in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after acquiring an additional 128 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in Gilead Sciences by 3.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 130 shares during the last quarter. Finally, Institutional & Family Asset Management LLC lifted its holdings in Gilead Sciences by 10.3% in the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 140 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Morgan Stanley decreased their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday. Barclays decreased their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, UBS Group decreased their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Hold” and an average price target of $83.87.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Gilead Sciences Stock Up 0.2 %

Gilead Sciences stock opened at $65.42 on Friday. Gilead Sciences, Inc. has a 1-year low of $64.63 and a 1-year high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The stock has a market cap of $81.45 billion, a PE ratio of 181.72, a P/E/G ratio of 1.17 and a beta of 0.19. The stock’s fifty day moving average is $71.28 and its two-hundred day moving average is $76.25.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 23.08% and a net margin of 1.76%. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same period last year, the firm earned $1.37 earnings per share. Gilead Sciences’s quarterly revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 3.82 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.